https://www.socictopen.socict.org/files/original/d1fdf07ec5a09635fa87a2c1e3692e8b.pdf 523fc20d126fec6bccc010cc0ed00fcc Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Coronavirus Description An account of the resource Dominio científico: Coronavirus Text A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text. Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Neutralizing antibodies against SARS-CoV-2: current understanding, challenge and perspective. Creator An entity primarily responsible for making the resource Yang Huang, Hui Sun, Hai Yu, Shaowei Li, Qingbing Zheng, Ningshao Xia Description An account of the resource The rapid emergence of Coronavirus disease-2019 (COVID-19) caused by severe acute respiratory syndrome 2 coronavirus (SARS-CoV-2) as a pandemic that presents an urgent human health crisis. Many SARS-CoV-2 neutralizing antibodies (NAbs) were developed with efficient therapeutic potential. NAbs-based therapeutics against SARS-CoV-2 are being expedited to preclinical and clinical studies with two antibody drugs, LY3819253 (LY-CoV555) and REGN-COV2 (REGN10933 and REGN10987), approved by the US Food and Drug Administration for emergency use authorization for treating COVID-19. In this review, we provide a systemic overview of SARS-CoV-2 specific or cross-reactive NAbs and discuss their structures, functions and neutralization mechanisms. We provide insight into how these NAbs specific recognize the spike protein of SARS-CoV-2 or cross-react to other CoVs. We also summarize the challenges of NAbs therapeutics such as antibody-dependent enhancement and viral escape mutations. Such evidence is urgently needed to the development of antibody therapeutic interventions that are likely required to reduce the global burden of COVID-19. Date A point or period of time associated with an event in the lifecycle of the resource 2020 Subject The topic of the resource spike protein, covid-19, SARS-CoV-2, neutralizing antibodies, hace2 Identifier An unambiguous reference to the resource within a given context 10.1093/abt/tbaa028 Source A related resource from which the described resource is derived Antibody therapeutics